Seeking women with microsatellite stable (MSS) recurrent or persistent endometrial cancer (EC) that has been treated with between one and three different types of chemotherapy for a study of an investigational drug combination to prevent the cancer from progressing.
Participants in this study will receive an infusion of the investigational drug combination every 21 days for up to 35 cycles.
What we're hoping for
We are studying if an investigational drug combination to activate the immune system to kill tumor cells and target folate receptor-alpha protein is safe and effective in preventing disease progression for severe endometrial cancer.
ClinicalTrials.gov Identifier: NCT03835819